While Abivax ADR has underperformed by -2.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABVX rose by 1278.42%, with highs and lows ranging from $109.71 to $4.77, whereas the simple moving average jumped by 163.40% in the last 200 days.
On November 06, 2025, Wolfe Research started tracking Abivax ADR (NASDAQ: ABVX) recommending Outperform. A report published by Barclays on October 13, 2025, Initiated its previous ‘Overweight’ rating for ABVX. Morgan Stanley also Upgraded ABVX shares as ‘Overweight’, setting a target price of $71 on the company’s shares in a report dated July 23, 2025. Morgan Stanley Initiated an Equal-Weight rating on March 20, 2025, and assigned a price target of $12. JMP Securities initiated its ‘Mkt Outperform’ rating for ABVX, as published in its report on December 04, 2024. Laidlaw’s report from July 29, 2024 suggests a price prediction of $48 for ABVX shares, giving the stock a ‘Buy’ rating. BTIG Research also rated the stock as ‘Buy’.
Analysis of Abivax ADR (ABVX)
In order to gain a clear picture of Abivax ADR’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -147.48% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.77, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.07M can be a very valuable indicator of volatility for ABVX stock. On a monthly basis, the volatility of the stock is set at 4.77%, whereas on a weekly basis, it is put at 5.52%, with a loss of -2.89% over the past seven days. Furthermore, long-term investors anticipate a median target price of $118.75, showing growth from the present price of $100.9, which can serve as yet another indication of whether ABVX is worth investing in or should be passed over.
How Do You Analyze Abivax ADR Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 11.68%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 30.88% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
